retatrutide type 2 diabetes trial results 28.7% Weight Loss in New Study – Dr Brad Stanfield Lilly's triple agonist achieves 16.8%

Notably, the clinical improvements in headache severity appeared to correlate more closely with reductions in insulin levels than with changes in glucose, both under fasting and postprandial conditions

M.HornC

Tirzepatide, for instance, stands out by targeting not only the GLP-1 receptor but also the glucose-dependent insulinotropic polypeptide (GIP) receptor, offering a dual mechanism of action

A role for PPAR- in the control of Gipr gene expression has previously been reported in studies of INS(832/13) cells

Its ability to engage GLP-1, GIP, and glucagon receptors has made it a subject of interest in multi-pathway signaling research

Annals of Translational Medicine, 11(2), pp.132132